10-Q: Eledon Pharmaceuticals Narrows Focus, Reports Reduced Loss

Eledon Pharmaceuticals reported a significantly reduced net loss for Q2 2025, driven by a decrease in warrant liabilities and strategic focus on kidney transplantation programs, while noting the need for additional financing for its ALS program.

Summary

• Net loss for the three months ended June 30, 2025, was $11.2 million, a significant improvement from $44.9 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $17.7 million, down from $68.5 million for the same period in 2024.
• Research and development expenses increased by $10.2 million for the three months ended June 30, 2025, and $16.3 million for the six months ended June 30, 2025, primarily due to increased activity in kidney transplantation programs and manufacturing.
• General and administrative expenses increased by $0.1 million for the three months and $1.0 million for the six months ended June 30, 2025, mainly due to increased professional services and personnel costs.
• The fair value of warrant liabilities decreased by $12.3 million for the three months and $22.4 million for the six months ended June 30, 2025, reflecting a decline in the company's stock price.
• Cash and cash equivalents and short-term investments totaled $107.6 million as of June 30, 2025.
• Working capital was $97.7 million and accumulated deficit was $373.3 million as of June 30, 2025.
• Enrollment in the Phase 2 BESTOW study for kidney transplantation was completed on September 4, 2024, with topline results anticipated in November 2025.
• Positive interim data from an investigator-initiated trial of tegoprubart in islet cell transplantation showed insulin independence and improved graft function in initial patients.
• The IgA Nephropathy (IgAN) program was deprioritized and discontinued in 2023.
• The company is unable to continue clinical development of tegoprubart for ALS without additional specific financing.

Sentiment

Score: 6

Explanation: The company shows significant progress in clinical trials for its lead candidate, particularly in kidney and islet cell transplantation, with promising early results. The reduction in net loss is positive, though largely driven by non-cash warrant revaluation. However, the continued reliance on external financing, especially for the ALS program, and the identified material weakness in internal controls, temper the overall positive sentiment.

Positives

• Significant reduction in net loss for both the three and six months ended June 30, 2025, compared to the prior year, primarily due to a favorable change in the fair value of warrant liabilities.
• Successful completion of enrollment in the Phase 2 BESTOW study for kidney transplantation, a key milestone for the lead drug candidate.
• Positive interim safety and efficacy results from the Phase 1b kidney transplantation trial, showing tegoprubart is generally safe, well-tolerated, and associated with improved renal function (mean eGFR 70.5 mL/min/1.73m2 after day 30, with two participants above 90 mL/min/1.73m2 at one year).
• Demonstrated potential to prevent acute and chronic transplant rejection without the need for Calcineurin Inhibitors (CNIs), mitigating associated side effects like nephrotoxicity, diabetes, and hypertension.
• Promising early data from the investigator-initiated islet cell transplantation trial, with initial patients achieving insulin independence and significantly higher islet engraftment compared to tacrolimus-treated patients.
• Tegoprubart has been successfully used in four xenotransplantation procedures, with two kidney recipients remaining alive with ongoing graft function.
• Phase 2a study of tegoprubart for ALS met primary endpoints of safety and tolerability, showing target engagement and reduction in pro-inflammatory biomarkers.

Negatives

• Continued significant operating losses and negative cash flows from operating activities, with a net loss of $17.7 million for the six months ended June 30, 2025.
• Accumulated deficit of $373.3 million as of June 30, 2025, indicating a history of unprofitability.
• Requires additional funding to complete the development of its lead drug candidate and to fund future operations, with no assurance of obtaining such capital on acceptable terms or at all.
• Inability to continue clinical development of tegoprubart for ALS without additional specific financing, despite positive Phase 2a results.
• Increased research and development expenses, driven by clinical trial activities and manufacturing costs, contributing to cash burn.
• Material weakness in internal control over financial reporting identified, leading to restatements of prior financial statements, indicating control deficiencies.

Risks

• Short operating history and shifts in business strategy make it difficult to evaluate future viability.
• Expectation to incur significant operating losses for several years and may never achieve or maintain profitability.
• Requirement for additional funding to complete drug development; inability to raise capital could force significant alteration of business strategy, curtailment of operations, or liquidation.
• Issuances of common stock, including from outstanding warrants or convertible securities, could result in significant dilution and cause stock price to fall.
• Product candidates are in early stages of clinical development and may not be successfully developed, leading to material harm if commercialization is unsuccessful or significantly delayed.
• Unfavorable global economic conditions, including inflation and interest rates, could adversely affect business and ability to obtain financing.
• Adverse conditions in financial markets, including bank failures, could affect liquidity and financial performance.
• Drug development is a lengthy, expensive process with uncertain outcomes, including failure to demonstrate safety and efficacy to regulatory authorities.
• Results of non-clinical studies and early clinical trials may not predict later-stage clinical trial results, and additional safety studies may be required.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals and increase expenses.
• Identification of serious adverse events or unacceptable side effects during development may lead to abandonment or limitation of product candidate development.
• Future success depends on ability to retain executives and key employees and attract qualified personnel.
• Failure or delays in obtaining required regulatory approvals, or approvals for narrow indications, could impair revenue generation.
• Legislation regulating pharmaceutical and healthcare industries may increase difficulty and cost of obtaining marketing approval and affect prices.
• Internal computer systems or those of third parties may fail or suffer security breaches, disrupting development programs or leading to data loss.
• Compromise of privacy, security, integrity, or confidentiality of sensitive information or failure to comply with data privacy obligations could materially affect business.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and third-party payers.
• Later discovery of less effectiveness or undesirable side effects post-marketing approval could compromise product marketability.
• Substantial competition from major pharmaceutical and biotechnology companies, including those with greater resources.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products could limit marketability and revenue.
• Reliance on third parties for manufacturing increases risk of insufficient quantities, unacceptable cost/quality, or delays.
• Dependence on Contract Research Organizations (CROs) and other third parties for testing means outcomes are partly beyond direct control.
• Inability to obtain and maintain intellectual property protection or insufficient scope of protection could allow competitors to commercialize similar products.
• Public health crises, including pandemics or epidemics, could adversely affect business operations and development activities.
• Stock price could be volatile and drop unexpectedly due to various factors, including clinical trial results, competition, and financial condition.
• Failure to establish and maintain proper and effective internal control over financial reporting could harm operating results and business operations.
• Provisions in corporate charter and Delaware law could make company acquisition more difficult and prevent attempts to replace management.

Future Outlook

The company expects to continue incurring net losses into the foreseeable future due to ongoing research and development activities. Existing cash, cash equivalents, and marketable securities are projected to fund planned operations for at least the next 12 months from the filing date. Additional financing will be required to fund future operations, particularly for the continued clinical development of tegoprubart for ALS. Topline results from the Phase 2 BESTOW study are anticipated in November 2025. The company is evaluating the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its financial statements and is assessing new FASB accounting standards updates for potential impact.

Management Comments

• We believe the central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention.
• We are unable to continue our clinical development of tegoprubart for people with ALS without additional financing.
• We expect that, based on our current operating plans, our existing cash, cash equivalents and marketable securities will be sufficient to fund our currently planned operations for at least the next 12 months from the filing date of these unaudited condensed consolidated financial statements.
• We anticipate it will require additional financing to fund its future operations.

Industry Context

Eledon Pharmaceuticals operates in the highly competitive clinical-stage biotechnology sector, focusing on immunology, specifically targeting the CD40 Ligand pathway. This pathway is a well-validated biological target with broad therapeutic potential in organ transplantation and neurodegenerative diseases like ALS. The company's strategy to develop tegoprubart for kidney transplantation addresses a critical unmet need for improved immunosuppression therapies, as current standard-of-care CNIs have significant side effects and limited long-term graft survival. The exploration of xenotransplantation and islet cell transplantation aligns with cutting-edge advancements in regenerative medicine and organ replacement. The ALS program, while promising in early stages, faces the common industry challenge of high development costs and the need for substantial, sustained financing. The industry is also navigating evolving regulatory landscapes and increasing pressures on drug pricing and reimbursement.

Comparison to Industry Standards

• In the Phase 1b kidney transplantation trial, tegoprubart demonstrated a mean eGFR of 70.5 mL/min/1.73m2 for all reported time points after day 30 post-transplant. This compares favorably to historical studies using standard-of-care CNI-based immunosuppression, which typically report aggregate mean estimated eGFRs of approximately 53 mL/min/1.73m2 during the first year after kidney transplant.
• Two participants in the Phase 1b trial completed 12 months on therapy post-transplant, both demonstrating mean eGFRs above 90 mL/min/1.73m2 at one-year post-transplant, significantly exceeding typical historical outcomes.
• The absence of hyperglycemia, new onset diabetes, or tremor in tegoprubart-treated patients in the Phase 1b trial contrasts with these being common side effects associated with standard-of-care CNI immunosuppression (e.g., tacrolimus).
• In the investigator-initiated islet cell transplantation study, islet engraftment measured by graft function was two to three times higher than that observed in comparable historical patients treated with tacrolimus-based immunosuppression, suggesting superior protection of transplanted islet cells.
• The company faces competition from major pharmaceutical and biotechnology companies like Novartis, Sanofi, UCB, Amgen, Bristol Myers Squibb, Tonix Pharmaceuticals, and Kiniksa Pharmaceuticals, many of whom have significantly greater financial resources and expertise in developing anti-CD40 and anti-CD40L therapeutics.
• For ALS, tegoprubart competes with FDA-approved therapeutics such as RADICAVA and riluzole, and numerous other branded and generic immunosuppressive agents, as well as other companies like Biogen, Ionis Pharmaceuticals, and Alexion Pharmaceuticals developing various therapeutic approaches.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from future capital raises, but also potential for value appreciation if clinical trials succeed and products are commercialized. The restatement due to internal control weakness may impact confidence.
• **Patients (Kidney Transplant):** Positive interim clinical data suggests tegoprubart could offer a safer and more effective alternative to current immunosuppression, potentially improving long-term graft survival and reducing side effects.
• **Patients (ALS):** Clinical development is stalled without additional financing, which could delay or prevent a potentially beneficial therapy from reaching this patient population.
• **Patients (Islet Cell Transplant):** Promising early data indicates tegoprubart could significantly improve outcomes for Type 1 Diabetes patients undergoing ICT, potentially leading to insulin independence.
• **Employees:** Increased headcount to support clinical development programs, but ongoing financial losses and need for capital raise could create uncertainty.
• **Creditors/Investors:** The company's recurring net losses and need for additional financing present a risk, but existing cash reserves are projected to last at least 12 months, and recent capital raises demonstrate ability to secure funding.

Next Steps

• Present topline results from the Phase 2 BESTOW study in November 2025.
• Enroll an additional six patients in the ongoing investigator-initiated islet cell transplantation study by the end of 2025.
• Seek additional financing to fund future operations, particularly for the continued clinical development of tegoprubart for ALS.
• Continue remediation efforts to address the identified material weakness in internal control over financial reporting.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Evaluate the impact of new FASB accounting standards (ASU No. 2023-09 and ASU No. 2024-03) on financial statement disclosures.

Key Dates

Recommendation

Eledon Pharmaceuticals shows promising clinical progress with tegoprubart, particularly in kidney and islet cell transplantation, which could address significant unmet medical needs. The reduction in net loss is a positive sign, though driven by non-cash factors. However, the company's continued reliance on external financing, especially for the ALS program, and the identified material weakness in internal controls, introduce considerable risk. While the long-term potential is there, the immediate future is highly dependent on successful capital raises and clinical trial outcomes, making it a 'hold' for seasoned investors who can tolerate high risk and monitor developments closely.

Keywords

Biotechnology, Clinical Stage, Immunology, CD40 Ligand, Tegoprubart, Kidney Transplantation, Organ Rejection, ALS, Amyotrophic Lateral Sclerosis, Xenotransplantation, Islet Cell Transplantation, Drug Development, Clinical Trials, SEC Filing, 10-Q, Pharmaceuticals, Biologics, Immunosuppression